This wound-care nano float has gotten some high profile interest recently, and combined with strong technicals, we believe now is the time to follow the money.
Tag: biotech
This Cell Therapy Stock Is On The Brink Of An Impressive Growth Spurt
This cell therapy powerhouse has taken a significant step forward in its mission to develop cutting-edge cell therapy platforms for cancer treatment. The company has secured exclusive rights to negotiate the acquisition of VyGen-Bio, Inc. or its assets, an opportunity that the company believes holds great promise for enhancing its oncology pipeline and advancing transformative cell and gene therapies.
Parkinson’s Treatment FDA Approval Solidifies Massive Upside Potential
After the FDA delivered an approval to this low float biotech, its already mammoth potential grew even bigger. In line with the primed nano-cap market, see why this company is a potential goldmine.
Orphan Drug Designation and New Patent Means Immense Potential For This Micro-Float
This Orphan Drug Designated micro-float was just granted it’s 8th Patent after bouncing off it’s 52-week low, prompting a Wall St. Analyst to assign a +500% price target.
Senior Life Sciences Analyst From Noble Financial Says This Gene Therapy Stock Could Climb Over 400%
Robert LeBoyer, a Senior Life Sciences Analyst at Noble Financial doubled down on his Outperform rating with a 400% upside after this company signed an exclusive University license agreement.
$CMND is Taking Wall Street by Surprise
Biotech companies are responsible for some of the most innovative developments in the world. Learn how this company is making it’s mark on the industry, and what that could mean for your portfolio.
$BTCY: Pushing a $219B Medical Industry Forward
Named one of Time’s “Best Inventions of 2022,” a new product from Biotricity is pushing heart disease treatment forward. Today, we’re taking a closer look at NASDAQ: $BTCY.
Revolutionizing The Biotech Space
Did we just find biotech next’s unicorn? Find out how this biotech company’s product quality and uniquely scalable product catalog could make this a stock to watch.
Huge Break-through Treatment Leading To Huge Break-Out Profits?
An answer to myeloid leukemia could be imminent with over 773 percent potential upside, according to an HC Wainwright Analyst. Take a moment to learn why Actinium Pharmaceuticals might be behind biotech’s next generational leap forward.
Faster, Easier Cancer Detection
Early detection is key when it comes to treating cancer. Let’s take a look at how this company is breaking new ground in a $3.7 billion market with faster and easier methods of colorectal cancer screening.